Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Present and future strategies in the treatment of renal anaemia
Autore:
Macdougall, IC;
Indirizzi:
Kings Coll Hosp, Dept Renal Med, Renal Unit, London SE22 8PT, England Kings Coll Hosp London England SE22 8PT l Unit, London SE22 8PT, England
Titolo Testata:
NEPHROLOGY DIALYSIS TRANSPLANTATION
, volume: 16, anno: 2001, supplemento:, 5
pagine: 50 - 55
SICI:
0931-0509(2001)16:<50:PAFSIT>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT-HUMAN-ERYTHROPOIETIN; HEMODIALYSIS-PATIENTS; PREDIALYSIS PATIENTS; INTRAVENOUS IRON; STIMULATING PROTEIN; DIALYSIS PATIENTS; ANEMIA; DISEASE; EPOETIN; THERAPY;
Keywords:
epoetin; epoetin resistance; erythropoietic substances; renal anaemia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Macdougall, IC Kings Coll Hosp, Dept Renal Med, Renal Unit, E Dulwich Grove, London SE22 8PT, England Kings Coll Hosp E Dulwich Grove London EnglandSE22 8PT nd
Citazione:
I.C. Macdougall, "Present and future strategies in the treatment of renal anaemia", NEPH DIAL T, 16, 2001, pp. 50-55

Abstract

Recombinant human erythropoietin therapy has transformed the management ofrenal anaemia over the last decade or so. We have learned much about the optimum regimens for using this drug, including the route of administration,dosage frequency, use of iron supplementation, and management of poor response. Thus, dosage requirements of epoetin are generally lower if the drug is administered subcutaneously, and the most commonly used dosage frequencyis two or three times weekly. The vast majority of patients respond very well to treatment, but similar to5-10% of patients show some resistance to epoetin, the most common cause of which is iron deficiency. The presence of infection or inflammation and under-dialysis are other important causes of a poor response to epoetin. There is increasing interest in treating renal anaemia at an earlier stage in the course of the disease, and there is muchcircumstantial evidence to support this strategy. This usually involves giving epoetin to pre-dialysis patients, and a study has also recently commenced to investigate the effects of preventing renal anaemia ever developing. Other erythropoietic substances are being developed, and the first of these to be ready for clinical use is novel erythropoiesis stimulating protein (NESP), which is an analogue of erythropoietin containing two extra N-linked carbohydrate side-chains. Other potential erythropoietic substances are still at the laboratory stage of development, but may be available for therapeutic use in the next decade or so.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 22:39:24